ArticleAntimicrobial agents and chemotherapy2010
Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rate of polymyxin resistance among Acinetobacter baumannii recovered from hospitalized patients: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Pooled it
- Sulbactam-Durlobactam for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- Antivirulence drugs against Acinetobacter baumannii: where do they stand?World journal of microbiology & biotechnology · 2025Review
- Blue benzoquinone from scorpion venom shows bactericidal activity against drug-resistant strains of the priority pathogen Acinetobacter baumannii.The Journal of antibiotics · 2025Article
- Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, inAntibiotics (Basel, Switzerland) · 2024Article
- Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Epidemiology and antimicrobial resistance trends ofFrontiers in public health · 2023Article
- Review
- Molecular epidemiology and carbapenem resistance characteristics ofFrontiers in microbiology · 2022Article
- A short synthetic peptide, based on LyeTx I from Lycosa erythrognatha venom, shows potential to treat pneumonia caused by carbapenem-resistant Acinetobacter baumannii without detectable resistance.The Journal of antibiotics · 2021Article
- Mechanism of azithromycin in airway diseases.The Journal of international medical research · 2020Review
- Does an antimicrobial stewardship program for Carbapenem use reduce Costs? An observation in Tehran, Iran.Caspian journal of internal medicine · 2020Article
- Carbapenem-Nonsusceptible Acinetobacter baumannii, 8 US Metropolitan Areas, 2012-2015.Emerging infectious diseases · 2018Article
- Attributable Mortality of Healthcare-Associated Infections Due to Multidrug-Resistant Gram-Negative Bacteria and Methicillin-Resistant Staphylococcus Aureus.Infection control and hospital epidemiology · 2017Article
- Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review.Infectious diseases and therapy · 2017Review
- The Impact of Reducing Antibiotics on the Transmission of Multidrug-Resistant Organisms.Infection control and hospital epidemiology · 2017Article
- Spread of theFrontiers in microbiology · 2017Article
- Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.Antimicrobial agents and chemotherapy · 2016Article
- Editorial commentary: Polymyxin-resistant Acinetobacter baumannii: urgent action needed.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Article
- Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A phenotypic and genotypic analysis of Acinetobacter baumannii was conducted from 2003 to 2008 in Detroit, MI. The incidence of A. baumannii increased from 1.7 to 3.7/1,000 patient days during the study period. Susceptibility to ampicillin-sulbactam and imipenem decreased from approximately 90% to approximately 40%. Genotyping revealed polyclonality, suggesting either emergence of multiple resistant strains or spread of a common genetic element. The sharp rise mandates major multidisciplinary interventions to optimize management of this multidrug-resistant pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.